504 related articles for article (PubMed ID: 32153556)
1. Quinolinate as a Marker for Kynurenine Metabolite Formation and the Unresolved Question of NAD
Moffett JR; Arun P; Puthillathu N; Vengilote R; Ives JA; Badawy AA; Namboodiri AM
Front Immunol; 2020; 11():31. PubMed ID: 32153556
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia.
Saito K; Nowak TS; Markey SP; Heyes MP
J Neurochem; 1993 Jan; 60(1):180-92. PubMed ID: 8417138
[TBL] [Abstract][Full Text] [Related]
3. A mechanism for increased quinolinic acid formation following acute systemic immune stimulation.
Saito K; Crowley JS; Markey SP; Heyes MP
J Biol Chem; 1993 Jul; 268(21):15496-503. PubMed ID: 8340378
[TBL] [Abstract][Full Text] [Related]
4. Kynurenine pathway enzymes in brain: responses to ischemic brain injury versus systemic immune activation.
Saito K; Nowak TS; Suyama K; Quearry BJ; Saito M; Crowley JS; Markey SP; Heyes MP
J Neurochem; 1993 Dec; 61(6):2061-70. PubMed ID: 8245962
[TBL] [Abstract][Full Text] [Related]
5. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
[TBL] [Abstract][Full Text] [Related]
6. Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(-3-nitrophenyl)thiazol-2yl]-benzenesul fonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine hydroxylase.
Chiarugi A; Moroni F
Neuropharmacology; 1999 Aug; 38(8):1225-33. PubMed ID: 10462134
[TBL] [Abstract][Full Text] [Related]
7. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse.
Saito K; Markey SP; Heyes MP
Neuroscience; 1992 Nov; 51(1):25-39. PubMed ID: 1465184
[TBL] [Abstract][Full Text] [Related]
8. Tryptophan and the immune response.
Moffett JR; Namboodiri MA
Immunol Cell Biol; 2003 Aug; 81(4):247-65. PubMed ID: 12848846
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of kynurenine and tryptophan treatment on quinolinate immunoreactivity in rat lymphoid and non-lymphoid organs.
Moffett JR; Blinder KL; Venkateshan CN; Namboodiri MA
Cell Tissue Res; 1998 Sep; 293(3):525-34. PubMed ID: 9716743
[TBL] [Abstract][Full Text] [Related]
10. Selective metabolism of kynurenine in the spleen in the absence of indoleamine 2,3-dioxygenase induction.
Espey MG; Namboodiri MA
Immunol Lett; 2000 Jan; 71(1):67-72. PubMed ID: 10709788
[TBL] [Abstract][Full Text] [Related]
11. Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats.
Braidy N; Guillemin GJ; Mansour H; Chan-Ling T; Grant R
FEBS J; 2011 Nov; 278(22):4425-34. PubMed ID: 22032336
[TBL] [Abstract][Full Text] [Related]
12. 6-Chloro-D,L-tryptophan, 4-chloro-3-hydroxyanthranilate and dexamethasone attenuate quinolinic acid accumulation in brain and blood following systemic immune activation.
Saito K; Markey SP; Heyes MP
Neurosci Lett; 1994 Sep; 178(2):211-5. PubMed ID: 7824198
[TBL] [Abstract][Full Text] [Related]
13. Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the L-kynurenine and quinolinic acid pools in brain.
Kita T; Morrison PF; Heyes MP; Markey SP
J Neurochem; 2002 Jul; 82(2):258-68. PubMed ID: 12124427
[TBL] [Abstract][Full Text] [Related]
14. Species heterogeneity between gerbils and rats: quinolinate production by microglia and astrocytes and accumulations in response to ischemic brain injury and systemic immune activation.
Heyes MP; Saito K; Chen CY; Proescholdt MG; Nowak TS; Li J; Beagles KE; Proescholdt MA; Zito MA; Kawai K; Markey SP
J Neurochem; 1997 Oct; 69(4):1519-29. PubMed ID: 9326281
[TBL] [Abstract][Full Text] [Related]
15. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
[TBL] [Abstract][Full Text] [Related]
16. The kynurenine pathway activities in a sub-Saharan HIV/AIDS population.
Bipath P; Levay PF; Viljoen M
BMC Infect Dis; 2015 Aug; 15():346. PubMed ID: 26285873
[TBL] [Abstract][Full Text] [Related]
17. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
[TBL] [Abstract][Full Text] [Related]
18. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types.
Heyes MP; Chen CY; Major EO; Saito K
Biochem J; 1997 Sep; 326 ( Pt 2)(Pt 2):351-6. PubMed ID: 9291104
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the kynurenine metabolism pathway by Xiaoyao San and the underlying effect in the hippocampus of the depressed rat.
Wang J; Li X; He S; Hu L; Guo J; Huang X; Hu J; Qi Y; Chen B; Shang D; Wen Y
J Ethnopharmacol; 2018 Mar; 214():13-21. PubMed ID: 29217494
[TBL] [Abstract][Full Text] [Related]
20. Involvement of Indoleamine-2,3-Dioxygenase and Kynurenine Pathway in Experimental Autoimmune Encephalomyelitis in Mice.
Zarzecki MS; Cattelan Souza L; Giacomeli R; Silva MRP; Prigol M; Boeira SP; Jesse CR
Neurochem Res; 2020 Dec; 45(12):2959-2977. PubMed ID: 33040279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
